What is GoodRx Holdings, Inc.'s R&D?

GoodRx Holdings, Inc. (GDRX) reported R&D of $30.18M in Q1 2026.

How has GoodRx Holdings, Inc.'s R&D changed year-over-year?

GoodRx Holdings, Inc.'s R&D decreased by 3.1% year-over-year, from $31.14M to $30.18M.

What is the long-term trend for GoodRx Holdings, Inc.'s R&D?

Over 4 years (2021 to 2025), GoodRx Holdings, Inc.'s R&D has grown at a -1.0% compound annual growth rate (CAGR), from $125.86M to $121.03M.

Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.

GoodRx Holdings, Inc. GDRX R&D

R&D at other companies

DoximityDOCS

$39.11M+57.7%

Amneal Pharmaceuticals, Inc.AMRX

$38.38M-4.1%

OmnicellOMCL

$21.52M+4.8%

GE HealthCare TechnologiesGEHC

$345M+0.3%

Other financials

Income statement

See full

Revenue$194.0M-4.4%

Gross profit$173.9M-8.3%

Operating income$14.0M-40.1%

Net income$1.2M-89.4%

EPS (diluted)$0.00-100%

Balance sheet

See full

Cash & equivalents$235.7M-21.7%

Total debt$541.4M0.0%

Total equity$622.0M-4.9%

Total assets$2.0B+56.0%

Cash flow

See full

Operating cash flow$11.8M+25.8%

CapEx$1.1M+700%

Free cash flow$10.7M+15.4%

Valuation

See full

Market cap$911.04M-44.5%

Enterprise value$1.22B-35.4%

P/E44.3×-13.4×

P/S1.2×-0.9×

Profitability

See full

Gross margin91.8%-2.0pp

Operating margin9.9%-0.3pp

Net margin2.6%-1.0pp

FCF margin21%+2.3pp

Returns & leverage

See full

Return on equity3.2%-1.2pp

Debt / equity0.9×0.0×

Current ratio1.5×-3.8×

Where this comes from

Reported directly by GoodRx Holdings, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The official record: GoodRx Holdings, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about GoodRx Holdings, Inc.'s r&d.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is GoodRx Holdings, Inc.'s R&D?: GoodRx Holdings, Inc. (GDRX) reported R&D of $30.18M in Q1 2026.
How has GoodRx Holdings, Inc.'s R&D changed year-over-year?: GoodRx Holdings, Inc.'s R&D decreased by 3.1% year-over-year, from $31.14M to $30.18M.
What is the long-term trend for GoodRx Holdings, Inc.'s R&D?: Over 4 years (2021 to 2025), GoodRx Holdings, Inc.'s R&D has grown at a -1.0% compound annual growth rate (CAGR), from $125.86M to $121.03M.
What does R&D mean?: Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.